This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berlin, O. Articles by Woods, V. L. Search for Related Content PubMed PubMed Citation Articles by Berlin, O. Articles by Woods, V. L., Jr.

Development of a Novel Spontaneous Metastasis Model of Human Osteosarcoma Transplanted Orthotopically into Bone of Athymic Mice¹

Department of Orthopedics [Ö. B., R. D., W. A., D. A., V. L. W.] and Medicine [V. L. W.], University of California at San Diego Medical Center, San Diego, California 92103-8894, and Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 20829 [D. S.]

There is a pressing need for in vivo models in which potential antitumor agents can be tested for their ability to inhibit the growth and metastatic spread of human sarcomas. A recent advance in this regard has been the development of a v-Ki-ras-oncogene-transformed human osteosarcoma cell line (KRIB) that efficiently colonizes the lungs of athymic nude mice when cells (1 x 10⁵) are administered by i.v. injection. In the present study, we have utilized this cell line to develop a spontaneous metastasis model in which a small number of tumor cells are injected into the tibial bones of athymic mice. When as few as 1000 KRIB cells are orthotopically implanted into the tibial bones of nude mice, bone tumors, which are radiographically and histologically similar to primary human osteosarcoma, develop within 4 weeks. Furthermore, as in the human disease, cells from these primary tumors subsequently seed the animals' lungs, resulting in reproducible and quantifiable pulmonary metastasis evident both upon gross inspection of the lungs and histologically 6 weeks after tumor inoculation. Surgical amputation of the tumor inoculation site up to 2 weeks after tumor injection prevents pulmonary metastasis, indicating that substantial local (tibial) growth and invasion of the primary tumor for at least 2 weeks is required for subsequent metastasis. Implantation of s.c. 5000 KRIB cells fails to produce local or metastatic tumors. We anticipate that this model will prove to be a powerful tool with which to study the mechanisms of human osteosarcoma growth and pulmonary metastasis, and to assess the efficacy of promising therapeutic agents.

¹ These studies were supported by NIH Grants CA 58527, CA 28896, HL30480, AGO7996, AR 28467, AR07484, AR04115, and AR34264; The Swedish Cancer Society; Faculty of Medicine, University of Göteborg, Sweden; The Assar Gabrielsson Foundation, The Swedish Orthopaedic Association; The Swedish Society of Medicine; The W:6 Society; and a grant from the La Jolla Cancer Research Foundation.

² To whom requests for reprints should be addressed, at Section of Orthopaedic Oncology, Department of Orthopaedics, Sahlgren Hospital, S-41345, Göteborg, Sweden.

Received 3/29/93. Accepted 8/ 4/93.

This article has been cited by other articles:

				K. E. COMSTOCK, C. L. HALL, S. DAIGNAULT, S. A. MANDLEBAUM, C. YU, and E. T. KELLER A Bioluminescent Orthotopic Mouse Model of Human Osteosarcoma that Allows Sensitive and Rapid Evaluation of New Therapeutic Agents In Vivo In Vivo, September 1, 2009; 23(5): 661 - 668. [Abstract] [Full Text] [PDF]

				A. Labrinidis, S. Hay, V. Liapis, V. Ponomarev, D. M. Findlay, and A. Evdokiou Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model Clin. Cancer Res., May 15, 2009; 15(10): 3451 - 3461. [Abstract] [Full Text] [PDF]

				A. Labrinidis, P. Diamond, S. Martin, S. Hay, V. Liapis, I. Zinonos, N. A. Sims, G. J. Atkins, C. Vincent, V. Ponomarev, et al. Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma Clin. Cancer Res., March 15, 2009; 15(6): 1998 - 2009. [Abstract] [Full Text] [PDF]

				V. O. Lewis, M. G. Ozawa, M. T. Deavers, G. Wang, T. Shintani, W. Arap, and R. Pasqualini The Interleukin-11 Receptor {alpha} as a Candidate Ligand-Directed Target in Osteosarcoma: Consistent Data from Cell Lines, Orthotopic Models, and Human Tumor Samples Cancer Res., March 1, 2009; 69(5): 1995 - 1999. [Abstract] [Full Text] [PDF]

				A. Ketola, A. Hinkkanen, F. Yongabi, P. Furu, A.-M. Maatta, T. Liimatainen, R. Pirinen, M. Bjorn, T. Hakkarainen, K. Makinen, et al. Oncolytic Semliki Forest Virus Vector as a Novel Candidate against Unresectable Osteosarcoma Cancer Res., October 15, 2008; 68(20): 8342 - 8350. [Abstract] [Full Text] [PDF]

				P. Zhang, Y. Yang, P. A. Zweidler-McKay, and D. P.M. Hughes Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis Clin. Cancer Res., May 15, 2008; 14(10): 2962 - 2969. [Abstract] [Full Text] [PDF]

				L. M. Thai, A. Labrinidis, S. Hay, V. Liapis, S. Bouralexis, K. Welldon, B. J. Coventry, D. M. Findlay, and A. Evdokiou Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res., May 15, 2006; 66(10): 5363 - 5370. [Abstract] [Full Text] [PDF]

				E. C. McGary, A. Heimberger, L. Mills, K. Weber, G. W. Thomas, M. Shtivelband, D. C. Lev, and M. Bar-Eli A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells In Vivo Clin. Cancer Res., December 15, 2003; 9(17): 6560 - 6566. [Abstract] [Full Text] [PDF]

				E. C. McGary, K. Weber, L. Mills, M. Doucet, V. Lewis, D. C. Lev, I. J. Fidler, and M. Bar-Eli Inhibition of Platelet-derived Growth Factor-mediated Proliferation of Osteosarcoma Cells by the Novel Tyrosine Kinase Inhibitor STI571 Clin. Cancer Res., November 1, 2002; 8(11): 3584 - 3591. [Abstract] [Full Text] [PDF]

				J. L. Fisher, P. S. Mackie, M. L. Howard, H. Zhou, and P. F. M. Choong The Expression of the Urokinase Plasminogen Activator System in Metastatic Murine Osteosarcoma: An in Vivo Mouse Model Clin. Cancer Res., June 1, 2001; 7(6): 1654 - 1660. [Abstract] [Full Text] [PDF]